Cargando…

Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats

BACKGROUND: A platinum-containing anti-cancer agent, oxaliplatin (L-OHP), is known to induce peripheral neuropathy, including erectile dysfunction (ED) as a side effect, while Gosha-jinki-gan (GJG) is a traditional Japanese herbal medicine mainly used for peripheral neuropathy. AIM: To investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kataoka, Tomoya, Kawaki, Yuto, Kito, Yohei, Suzuki, Jun, Mori, Taiki, Hotta, Yuji, Sanagawa, Akimasa, Kawade, Yoshihiro, Maeda, Yasuhiro, Furukawa-Hibi, Yoko, Kimura, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023251/
https://www.ncbi.nlm.nih.gov/pubmed/35065470
http://dx.doi.org/10.1016/j.esxm.2021.100484
_version_ 1784690300043657216
author Kataoka, Tomoya
Kawaki, Yuto
Kito, Yohei
Suzuki, Jun
Mori, Taiki
Hotta, Yuji
Sanagawa, Akimasa
Kawade, Yoshihiro
Maeda, Yasuhiro
Furukawa-Hibi, Yoko
Kimura, Kazunori
author_facet Kataoka, Tomoya
Kawaki, Yuto
Kito, Yohei
Suzuki, Jun
Mori, Taiki
Hotta, Yuji
Sanagawa, Akimasa
Kawade, Yoshihiro
Maeda, Yasuhiro
Furukawa-Hibi, Yoko
Kimura, Kazunori
author_sort Kataoka, Tomoya
collection PubMed
description BACKGROUND: A platinum-containing anti-cancer agent, oxaliplatin (L-OHP), is known to induce peripheral neuropathy, including erectile dysfunction (ED) as a side effect, while Gosha-jinki-gan (GJG) is a traditional Japanese herbal medicine mainly used for peripheral neuropathy. AIM: To investigate the effect of GJG on L-OHP-induced ED in rats. METHODS: Twelve-week-old male Wister/ST rats were categorized into the following groups: Sham, Sham+GJG, L-OHP, and L-OHP+GJG (each n = 10). The L-OHP and L-OHP+GJG groups were injected intravenously with L-OHP (4 mg/kg) for 2 consecutive days in the first week. Statistical significance was determined using Bonferroni's multiple comparison test. OUTCOMES: At the end of the study period, erectile function was evaluated by measuring intracavernosal pressure (ICP) and mean arterial pressure (MAP) after cavernous nerve stimulation. Western blot analysis was used to assess the neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) levels, and quantitative polymerase chain reaction was used to assess the expression of phosphodiesterase-5 (PDE-5) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-1. RESULTS: The ICP/MAP ratio of L-OHP rats (0.34 ± 0.06) was significantly lower than that of Sham rats (0.67 ± 0.03, P < .01), however, the ICP/MAP ratio of L-OHP+GJG rats (0.55 ± 0.01) was significantly higher than that of L-OHP rats (P < .01). There were no significant differences in the nNOS and eNOS protein expression between both groups (P > .05). GJG administration significantly decreased PDE-5 and NADPH oxidase-1 messenger RNA expressions in the L-OHP+GJG group. CLINICAL TRANSLATION: This animal model study suggests that GJG might be effective for erectile function in cancer survivors. STRENGTHS & LIMITATIONS: Our study identified that GJG had no notable side effects in the treated group. Further investigation of the cavernous nerve would also help elucidate the mechanism of GJG effect, which is a limitation of this study. CONCLUSION: We found that GJG administration improved L-OHP-induced ED by improving transcriptional PDE-5 expression. Kataoka T, Kawaki Y, Kito Y, et al. Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats. Sex Med 2022;10:100484.
format Online
Article
Text
id pubmed-9023251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90232512022-04-22 Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats Kataoka, Tomoya Kawaki, Yuto Kito, Yohei Suzuki, Jun Mori, Taiki Hotta, Yuji Sanagawa, Akimasa Kawade, Yoshihiro Maeda, Yasuhiro Furukawa-Hibi, Yoko Kimura, Kazunori Sex Med Original Research BACKGROUND: A platinum-containing anti-cancer agent, oxaliplatin (L-OHP), is known to induce peripheral neuropathy, including erectile dysfunction (ED) as a side effect, while Gosha-jinki-gan (GJG) is a traditional Japanese herbal medicine mainly used for peripheral neuropathy. AIM: To investigate the effect of GJG on L-OHP-induced ED in rats. METHODS: Twelve-week-old male Wister/ST rats were categorized into the following groups: Sham, Sham+GJG, L-OHP, and L-OHP+GJG (each n = 10). The L-OHP and L-OHP+GJG groups were injected intravenously with L-OHP (4 mg/kg) for 2 consecutive days in the first week. Statistical significance was determined using Bonferroni's multiple comparison test. OUTCOMES: At the end of the study period, erectile function was evaluated by measuring intracavernosal pressure (ICP) and mean arterial pressure (MAP) after cavernous nerve stimulation. Western blot analysis was used to assess the neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) levels, and quantitative polymerase chain reaction was used to assess the expression of phosphodiesterase-5 (PDE-5) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-1. RESULTS: The ICP/MAP ratio of L-OHP rats (0.34 ± 0.06) was significantly lower than that of Sham rats (0.67 ± 0.03, P < .01), however, the ICP/MAP ratio of L-OHP+GJG rats (0.55 ± 0.01) was significantly higher than that of L-OHP rats (P < .01). There were no significant differences in the nNOS and eNOS protein expression between both groups (P > .05). GJG administration significantly decreased PDE-5 and NADPH oxidase-1 messenger RNA expressions in the L-OHP+GJG group. CLINICAL TRANSLATION: This animal model study suggests that GJG might be effective for erectile function in cancer survivors. STRENGTHS & LIMITATIONS: Our study identified that GJG had no notable side effects in the treated group. Further investigation of the cavernous nerve would also help elucidate the mechanism of GJG effect, which is a limitation of this study. CONCLUSION: We found that GJG administration improved L-OHP-induced ED by improving transcriptional PDE-5 expression. Kataoka T, Kawaki Y, Kito Y, et al. Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats. Sex Med 2022;10:100484. Elsevier 2022-01-19 /pmc/articles/PMC9023251/ /pubmed/35065470 http://dx.doi.org/10.1016/j.esxm.2021.100484 Text en Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Kataoka, Tomoya
Kawaki, Yuto
Kito, Yohei
Suzuki, Jun
Mori, Taiki
Hotta, Yuji
Sanagawa, Akimasa
Kawade, Yoshihiro
Maeda, Yasuhiro
Furukawa-Hibi, Yoko
Kimura, Kazunori
Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
title Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
title_full Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
title_fullStr Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
title_full_unstemmed Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
title_short Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
title_sort gosha-jinki-gan improved erectile dysfunction caused by anti-cancer agent oxaliplatin by decreasing transcriptional expression of phosphodiesterase-5 in rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023251/
https://www.ncbi.nlm.nih.gov/pubmed/35065470
http://dx.doi.org/10.1016/j.esxm.2021.100484
work_keys_str_mv AT kataokatomoya goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT kawakiyuto goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT kitoyohei goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT suzukijun goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT moritaiki goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT hottayuji goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT sanagawaakimasa goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT kawadeyoshihiro goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT maedayasuhiro goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT furukawahibiyoko goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats
AT kimurakazunori goshajinkiganimprovederectiledysfunctioncausedbyanticanceragentoxaliplatinbydecreasingtranscriptionalexpressionofphosphodiesterase5inrats